PharVision Advisers’s GitLab GTLB Stock Holding History

PharVision Advisers’s Portfolio GTLB Stock Details GTLB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-5,535	Closed	-$208K	–	335
2025 Q4	$208K	Buy	+5,535	New	+$240K	0.11%	528

Other funds holding GTLB

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Impactive Capital New York City, New York $1.38B AUM 1.92% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

CIP

Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return

Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

PharVision Advisers's GTLB Position: Q1 2026 in Review

PharVision Advisers sold out of GitLab (GTLB) in Q1 2026, closing a stake of 5,535 shares — an estimated $208K sold.

PharVision Advisers first reported a position in GTLB in Q4 2025 and held it in 1 quarter. The position peaked at $208K in Q4 2025. 366 funds tracked by Wall St. Rank hold GTLB as of Q1 2026.

PharVision Advisers reported no remaining GitLab position as of Q1 2026 after selling out during the quarter.
PharVision Advisers sold 5,535 GitLab shares in Q1 2026, an estimated $208K.
PharVision Advisers first reported a position in GitLab in Q4 2025 and held it in 1 quarter.
PharVision Advisers's GitLab position peaked at $208K in Q4 2025.
366 funds tracked by Wall St. Rank held GitLab as of Q1 2026.

Based on PharVision Advisers's 13F filing for Q1 2026, filed 22 Apr 2026.